Company: ENTXW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001178913-25-003852
Chunk: 27

Company: Entera Bio Ltd.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 27
---
 17%

Revenues

Revenues for the nine months ended September 30, 2025 and 2024 were $42 thousand and $99 thousand, respectively, which were attributable to research services we provided pursuant to the research services agreement. The Company completed the first stage of its obligations under the research services agreement in the first quarter of 2025.

Cost of Revenues

Cost of revenues for the nine months ended September 30, 2025 and 2024 was $42 thousand and $90 thousand, respectively, which were attributable to research services we provided pursuant to the research services agreement. The Company completed the first stage of its obligations under the research services agreement in the first quarter of 2025.

Research and Development Expenses Research and development expenses for the nine months ended September 30, 2025 were $4.3 million as compared to $3.3 million for the nine months ended September 30, 2024. The increase of $1.0 million was primarily due to an increase of $0.7 million in other consulting fees, including regulatory expenses  in connection with filing of a type A meeting and ongoing optimization processes related to the preparation of the EB613 phase 3 program, an increase of $0.3 million in connection with our internal programs and collaboration programs, an increase of $0.2 million in  compensation and an increase of $0.1 million in other expenses. This increase was partially offset by a decrease of $0.3 million in materials and productions related to the preparation of the EB613 phase 3 study.

26

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2025 were $4.2 million as compared to $4.0 million for the nine months ended September 30, 2024. The increase was primarily due to an increase of $0.2 million of other consultants and an increase of $0.2 million in compensation. This increase was partially offset by a decrease of $0.1 million in legal fees, mainly related to IP costs, and a decrease of $0.1 million in other expenses.

Financial Income, Net

Financial income, net for the nine months ended September 30, 2025 and 2024 was $64 thousand and $65 thousand, respectively. Our financial income was composed mainly of interest income from bank deposits and exchange rate differences of certain currencies against our functional currency, which is the U.S. Dollar.

Liquidity and Capital Resources